Washington was one of two states nationwide in which the number of people buying health insurance through government-run exchanges went down in the second round of open enrollment, which ended in February. The decline was a modest 2 percent — but the state’s goal had been to show a sizable increase.
This all suggests that the vast majority of the post-recession slowdown is attributable to lower economy-wide price inflation along with some temporary noncyclical factors. Of the surprisingly small amount left to be explained by the recession and structural changes, I would attribute the greatest share to the recession.
As of October 17, 2014 small businesses (50 or fewer employees) now have a broader choice of small group insurance plans through the Washington State Health Benefit Exchange. Regrettably the HBE has chosen to push its plans even where those plans may not be the best solution for a small business or its workforce. The fact that they are using public funds to market this approach has raised additional concerns.
OP/ED-Biosimilar Drugs Require More Transparent Communication Between Patient and Pharmacist: SB 5935 Needs Work
Very recently during the 64th Legislature in the State of Washington, House Bill 1675 was introduced relating to the prescription of biological products and interchangeable biological products. The bill addressed the process through which a biosimilar that has been given ‘interchangeable’ status by the FDA can be substituted for the innovator biologic it mimics.